Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression

Sawako Miyoshi, Hitoshi Tsugawa, Juntaro Matsuzaki, Kenro Hirata, Hideki Mori, Hideyuki Saya, Takanori Kanai, Hidekazu Suzuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: Cancer stem cells (CSCs) play a critical role in resistance to chemotherapy. CD44 is a cell surface marker of CSCs. CD44 variant 9 (CD44v9) interacts with a cystine-glutamate antiporter (xCT) and is an unfavorable predictive factor in gastric cancer. We investigated the impact of CD44v9 expression on 5-fluorouracil (5-FU) resistance and the efficacy of the xCT inhibitor, sulfasalazine (SASP), in improving drug resistance. Materials and Methods: The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments. Results: CD44v9 expression results in 5-FU resistance by increasing intracellular glutathione and suppressing the drug-induced production of reactive oxygen species (ROS). SASP improved the drug sensitivity of CD44v9-expressing cells. Conclusion: Inhibition of xCT improved the clinical efficacy of chemotherapy against gastric cancer. CD44v9 expression can be a novel biomarker to predict resistance against 5-FU in gastric cancer.

Original languageEnglish
Pages (from-to)6163-6170
Number of pages8
JournalAnticancer Research
Volume38
Issue number11
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Fluorouracil
Stomach Neoplasms
Neoplastic Stem Cells
Antiporters
Drug Therapy
Sulfasalazine
Cystine
Drug Resistance
Pharmaceutical Preparations
Glutathione
Glutamic Acid
Reactive Oxygen Species
Plasmids
Biomarkers
Cell Line

Keywords

  • 5-fluorouracil
  • Cancer stem cells
  • CD44
  • CD44 variant 9
  • Gastric cancer
  • Sulfasalazine
  • xCT inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression. / Miyoshi, Sawako; Tsugawa, Hitoshi; Matsuzaki, Juntaro; Hirata, Kenro; Mori, Hideki; Saya, Hideyuki; Kanai, Takanori; Suzuki, Hidekazu.

In: Anticancer Research, Vol. 38, No. 11, 01.11.2018, p. 6163-6170.

Research output: Contribution to journalArticle

@article{982d428a60aa4f87aeea05a1855b97c7,
title = "Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression",
abstract = "Background/Aim: Cancer stem cells (CSCs) play a critical role in resistance to chemotherapy. CD44 is a cell surface marker of CSCs. CD44 variant 9 (CD44v9) interacts with a cystine-glutamate antiporter (xCT) and is an unfavorable predictive factor in gastric cancer. We investigated the impact of CD44v9 expression on 5-fluorouracil (5-FU) resistance and the efficacy of the xCT inhibitor, sulfasalazine (SASP), in improving drug resistance. Materials and Methods: The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments. Results: CD44v9 expression results in 5-FU resistance by increasing intracellular glutathione and suppressing the drug-induced production of reactive oxygen species (ROS). SASP improved the drug sensitivity of CD44v9-expressing cells. Conclusion: Inhibition of xCT improved the clinical efficacy of chemotherapy against gastric cancer. CD44v9 expression can be a novel biomarker to predict resistance against 5-FU in gastric cancer.",
keywords = "5-fluorouracil, Cancer stem cells, CD44, CD44 variant 9, Gastric cancer, Sulfasalazine, xCT inhibitor",
author = "Sawako Miyoshi and Hitoshi Tsugawa and Juntaro Matsuzaki and Kenro Hirata and Hideki Mori and Hideyuki Saya and Takanori Kanai and Hidekazu Suzuki",
year = "2018",
month = "11",
day = "1",
doi = "10.21873/anticanres.12969",
language = "English",
volume = "38",
pages = "6163--6170",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression

AU - Miyoshi, Sawako

AU - Tsugawa, Hitoshi

AU - Matsuzaki, Juntaro

AU - Hirata, Kenro

AU - Mori, Hideki

AU - Saya, Hideyuki

AU - Kanai, Takanori

AU - Suzuki, Hidekazu

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background/Aim: Cancer stem cells (CSCs) play a critical role in resistance to chemotherapy. CD44 is a cell surface marker of CSCs. CD44 variant 9 (CD44v9) interacts with a cystine-glutamate antiporter (xCT) and is an unfavorable predictive factor in gastric cancer. We investigated the impact of CD44v9 expression on 5-fluorouracil (5-FU) resistance and the efficacy of the xCT inhibitor, sulfasalazine (SASP), in improving drug resistance. Materials and Methods: The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments. Results: CD44v9 expression results in 5-FU resistance by increasing intracellular glutathione and suppressing the drug-induced production of reactive oxygen species (ROS). SASP improved the drug sensitivity of CD44v9-expressing cells. Conclusion: Inhibition of xCT improved the clinical efficacy of chemotherapy against gastric cancer. CD44v9 expression can be a novel biomarker to predict resistance against 5-FU in gastric cancer.

AB - Background/Aim: Cancer stem cells (CSCs) play a critical role in resistance to chemotherapy. CD44 is a cell surface marker of CSCs. CD44 variant 9 (CD44v9) interacts with a cystine-glutamate antiporter (xCT) and is an unfavorable predictive factor in gastric cancer. We investigated the impact of CD44v9 expression on 5-fluorouracil (5-FU) resistance and the efficacy of the xCT inhibitor, sulfasalazine (SASP), in improving drug resistance. Materials and Methods: The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments. Results: CD44v9 expression results in 5-FU resistance by increasing intracellular glutathione and suppressing the drug-induced production of reactive oxygen species (ROS). SASP improved the drug sensitivity of CD44v9-expressing cells. Conclusion: Inhibition of xCT improved the clinical efficacy of chemotherapy against gastric cancer. CD44v9 expression can be a novel biomarker to predict resistance against 5-FU in gastric cancer.

KW - 5-fluorouracil

KW - Cancer stem cells

KW - CD44

KW - CD44 variant 9

KW - Gastric cancer

KW - Sulfasalazine

KW - xCT inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85056076595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056076595&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12969

DO - 10.21873/anticanres.12969

M3 - Article

VL - 38

SP - 6163

EP - 6170

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -